Strober, B.; Tada, Y.; Mrowietz, U.; Lebwohl, M.; Foley, P.; Langley, R. G.; Barker, J.; Wang, M.; Vanvoorden, V.; Szilagyi, B.; Ciaravino, V.; Paul, C. Bimekizumab Maintenance of Response through Three Years in Patients With Moderate to Severe Plaque Psoriasis Who Responded at Week 16: Results from the BE BRIGHT Open-Label Extension Trial. J of Skin 2022, 6, s65.